|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gupta S, Kong W, Peng Y, Miao Q and
Mackillop WJ: Temporal trends in the incidence and survival of
cancers of the upper aerodigestive tract in Ontario and the United
States. Int J Cancer. 125:2159–2165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wikner J, Gröbe A, Pantel K and Riethdorf
S: Squamous cell carcinoma of the oral cavity and circulating
tumour cells. World J Clin Oncol. 5:114–124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP and Chen CZ: Micromanagers of
gene expression: The potentially widespread influence of metazoan
microRNAs. Nat Rev Genet. 5:396–400. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Winther M, Alsner J, Tramm T, Baeksgaard
L, Holtved E and Nordsmark M: Evaluation of miR-21 and miR-375 as
prognostic biomarkers in esophageal cancer. Acta Oncol.
54:1582–1591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu A, Huang JJ, Xu WH, Jin XJ, Li JP, Tang
YJ, Huang XF, Cui HJ, Sun GB, Li RL, et al: miR-21/miR-375 ratio is
an independent prognostic factor in patients with laryngeal
squamous cell carcinoma. Am J Cancer Res. 5:1775–1785.
2015.PubMed/NCBI
|
|
9
|
Mao Q, Quan T, Luo B, Guo X, Liu L and
Zheng Q: miR-375 targets KLF4 and impacts the proliferation of
colorectal carcinoma. Tumour Biol. 37:463–471. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia L, Huang Y, Zheng Y, Lyu M, Zhang C,
Meng Z, Gan Y and Yu G: miR-375 inhibits cell growth and correlates
with clinical outcomes in tongue squamous cell carcinoma. Oncol
Rep. 33:2061–2071. 2015.PubMed/NCBI
|
|
11
|
Song L, Liu S, Zeng S, Zhang L and Li X:
miR-375 modulates radiosensitivity of HR-HPV-positive cervical
cancer cells by targeting UBE3A through the p53 pathway. Med Sci
Monit. 21:2210–2217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi W, Yang J, Li S, Shan X, Liu X, Hua H,
Zhao C, Feng Z, Cai Z, Zhang L, et al: Potential involvement of
miR-375 in the premalignant progression of oral squamous cell
carcinoma mediated via transcription factor KLF5. Oncotarget.
6:40172–40185. 2015.PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu X and Li Z: MicroRNA expression and its
implications for diagnosis and therapy of tongue squamous cell
carcinoma. J Cell Mol Med. 20:10–60. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu H, Yang Y, Zhao H, Yang X, Luo Y, Ren
Y, Liu W and Li N: Serum miR-483-5p: A novel diagnostic and
prognostic biomarker for patients with oral squamous cell
carcinoma. Tumour Biol. 37:447–453. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saad MA, Kuo SZ, Rahimy E, Zou AE,
Korrapati A, Rahimy M, Kim E, Zheng H, Yu MA, Wang-Rodriguez J and
Ongkeko WM: Alcohol-dysregulated miR-30a and miR-934 in head and
neck squamous cell carcinoma. Mol Cancer. 14:1812015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoon AJ, Wang S, Shen J, Robine N,
Philipone E, Oster MW, Nam A and Santella RM: Prognostic value of
miR-375 and miR-214-3p in early stage oral squamous cell carcinoma.
Am J Transl Res. 6:580–592. 2014.PubMed/NCBI
|
|
18
|
Siow MY, Ng LP, Vincent-Chong VK,
Jamaludin M, Abraham MT, Rahman ZA Abdul, Kallarakkal TG, Yang YH,
Cheong SC and Zain RB: Dysregulation of miR-31 and miR-375
expression is associated with clinical outcomes in oral carcinoma.
Oral Dis. 20:345–351. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Katano M, Nakamura M, Fujimoto K, Miyazaki
K and Morisaki T: Prognostic value of platelet-derived growth
factor-A (PDGF-A) in gastric carcinoma. Ann Surg. 227:365–371.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jones AC, Antillon KS, Jenkins SM, Janos
SN, Overton HN, Shoshan DS, Fischer EG, Trujillo KA and Bisoffi M:
Prostate field cancerization: Deregulated expression of macrophage
inhibitory cytokine 1 (MIC-1) and platelet derived growth factor A
(PDGF-A) in tumor adjacent tissue. PLoS One. 10:e01193142015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mishra A, Ormerod AK, Cibull ML, Spear BT,
Kraner SD and Kaetzel DM: PDGF-A promoter and enhancer elements
provide efficient and selective antineoplastic gene therapy in
multiple cancer types. Cancer Gene Ther. 16:298–309. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu G, Zhou A, Xue J, Huang C, Zhang X,
Kang SH, Chiu WT, Tan C, Xie K, Wang J and Huang S: FoxM1 promotes
breast tumorigenesis by activating PDGF-A and forming a positive
feedback loop with the PDGF/AKT signaling pathway. Oncotarget.
6:11281–11294. 2015. View Article : Google Scholar : PubMed/NCBI
|
